Get started
IRulya Therapeutics Inc. logo

IRLA

NASDAQ

IRulya Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2019
Follow + get alerts
Website

IRulya Therapeutics Inc. (IRLA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for IRLA in the last 30 days.

Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.

Financial highlights

Full financials
Net income, TTM
-$92.48M
Free cash flow, TTM
-$47.00M
Cash
$115.98M

For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.

Latest news

0 items

No recent news.

IRLA FAQ

8 questions
  • What does IRulya Therapeutics Inc. do?
    Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase...
  • Is IRLA profitable?
    No. IRulya Therapeutics Inc. reported a net loss of $92.48M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does IRLA have?
    IRulya Therapeutics Inc. reported $115.98M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does IRLA stock trade?
    IRulya Therapeutics Inc. (IRLA) is listed on NASDAQ.
  • What sector and industry is IRLA in?
    IRulya Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did IRulya Therapeutics Inc. go public?
    IRulya Therapeutics Inc. (IRLA) completed its IPO in 2019.
  • What companies are similar to IRLA?
    Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IRLA side-by-side with any of them on Quantisnow.
  • How can I track IRLA on Quantisnow?
    Quantisnow aggregates IRulya Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRLA to receive live email and push alerts on every new disclosure.